Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.46 |
| ▸ | SYK | P43405 | 7/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3806721 | 1.00 | MAP3K5 (0.47) | MAP3K5EGFRSYKSCN9AJAK2 | |
| SCHEMBL3715143 | 0.83 | MAP3K5 (0.51) | MAP3K5EGFRSYKSCN9AJAK2 | |
| SCHEMBL913569 | 0.80 | EGFR (0.55) | MAP3K5EGFRSYKBTKMAPK8 | |
| SCHEMBL913566 | 0.80 | EGFR (0.55) | MAP3K5EGFRSYKBTKMAPK8 | |
| SCHEMBL3714738 | 0.79 | EGFR (0.53) | MAP3K5EGFRSYKJAK2BTK | |
| SCHEMBL913759 | 0.79 | MAP3K5 (0.52) | MAP3K5EGFRSYKSCN9ABTK | |
| SCHEMBL915078 | 0.78 | SYK (0.54) | MAP3K5EGFRSYKSCN9AITK | |
| SCHEMBL913568 | 0.78 | MAP3K5 (0.49) | MAP3K5EGFRSYKSCN9ABTK | |
| SCHEMBL913817 | 0.78 | JAK3 (0.55) | MAP3K5EGFRSYKITKJAK3 | |
| SCHEMBL914302 | 0.77 | MAP3K5 (0.51) | MAP3K5EGFRJAK2BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | claimed |